Objective -To present results from the NHS breast screening programme (NHSBSP) for the three year period 1990 to 1993, and to examine the extent to which interim targets are being met. Methods -Data have been collated from all screening programmes in the United Kingdom on standard "Korner" returns, supplemented for the year 1991/92 by data from the radiology quality assurance programme. Most of the data refer to the prevalent screening round, but some data on rescreening are also available. Results -The total cancer detection rate at prevalent screens was 6·011000, 18% being in situ cancers; the detection rate of invasive cancers~10 mm in diameter was 1·311000, but data on size were missing for 12% of cancers. Referral rates were significantly lower for programmes using" two view mammography at the prevalent screen than for those using single view, and cancer detection rates were significantly higher. For prevalent screens over the three year period, 70% ofprogrammes had a referral rate of~7%, 87% had a benign biopsy rate of~511000, and 79% had a cancer detection rate of~511000. By contrast, only 30% of programmes appeared to meet the target detection rate of >1· 5/ 1000 for invasive cancers~10 mm in diameter. Conclusions -While the majority of interim targets are being met by the NHSBSP, the rate of detection of small invasive cancers requires careful monitoring. Collection of more accurate data on size ofcancers and interval cancer rates will give a better indication of progress towards the target mortality reduction.
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The United Kingdom breast screening programme (NHSBSP) was established in 1988 on the recommendation of the Forrest Committee,' which examined the evidence available from several research studies, including the Swedish Two County trial, which showed a significant reduction in breast cancer mortality in women offered screening by mammography.
The United Kingdom programme aims to offer all women aged 50-64 years screening by mammography every three years. It was designed to be run by individual screening programmes, each with a target population of approximately 41 000 women in this age group, and each has a specialised assessment centre. Women are identified for call and recall for screening from the Family Health Service Authority (FHSA) registers. Until recently the national guidelines have been for single view mammography to be used; however, almost half the screening units have been using two view mammography throughout the prevalent screening round. Women found to have an abnormality on the initial mammogram are recalled to the assessment centre for further investigation, which may include further mammographic views, clinical examination, ultrasound, and fine needle aspiration (FNA) cytology.
Women aged 65 years and over are not routinely invited for screening, but may attend at their own request. Women below the age of 50 are not offered routine screening, but a randomised trial is in progress to investigate the effect of starting screening at age 40. A further trial is looking at the effect of a shorter screening interval.
The aim of the programme is to reduce mortality from breast cancer. The "Health of the Nation" strategy specified the target as being "to reduce the mortality from breast cancer in the population invited for screening by 25% by the year 2000".2 Given that most research trials of mammography screening have shown a reduction in mortality becoming apparent only after four to five years.?" it is clearly too soon at present to look for any reduction in breast cancer mortality in the United Kingdom as a result of screening. However, various targets for interim outcome measures have been set by the NHSBSP, and the extent to which these targets are being met by screening programmes will give a preliminary indication of how likely the national programme is to meet its primary target.
Results of the programme for the year 1991/ 92 were published in 1993. 6 The present paper combines data for a three year period to give a broader picture of the results of the United Kingdom programme so far.
Methods
This paper presents data for the three year period from 1st April 1990 to 31st March 1993.
The number of screening programmes in operation in England and Wales has increased steadily, reaching 72 in 1990/91 and 83 in 1992/93. The last screening programme began in January 1992. The three Welsh programmes are run jointly as "Breast Test Wales"" Scotland has seven programmes and Northern Ireland four. Each screening programme has a computerised data base and record system. There are currently four different software systems used by screening offices in England and Wales, with another in Scotland. Since 1990 these systems have been used to complete standard annual "Korner" returns on breast screening activity and findings. The returns for individual programmes have been collected and analysed by the Cancer Screening Evaluation Unit (CSEU) on behalf of the Department of Health. Scotland and Northern Ireland have each supplied one return for the country as a whole. They have been used here to produce rates of acceptance of screening invitations, and referral, biopsy, and cancer detection rates for different types of screen. "Prevalent" screens here are those in women being screened for the first time within the NHSBSP, while "incident" screens are those in women previously screened three years earlier within the programme.
Information has also been obtained from each programme, by means of a questionnaire, on the use of single or two view mammography, the use of mobile screening units, and the type of population (that is, urban or rural) covered by each programme.
Information on acceptance of screening invitations can be obtained from the standard screening programme returns; however, for most software systems it has not yet been possible to separate these acceptance figures into first and subsequent invitations or screens. A separate return produced from the FHSA computer system is intended to provide information on uptake of screening and population coverage, but accurate data are not yet available.
The acceptance rates are derived from a cross sectional analysis, whereas the screening outcome figures are taken from analyses of cohorts of women screened.
Data for the individual screening programmes have been taken from the standard returns. Where problems with data failing to be recorded on the computer system have clearly led to missing data, these returns have been excluded from the relevant analyses. Such problems were greatest in the classification of cancers by size, and hence calculations of the rates of in situ cancers, and of cancers in different size categories, are based on fewer returns than other results. Data on in situ cancers and It is possible that for the year 1990/91, biopsy and cancer detection rates may be underestimated, and results for this year will differ slightly from those published earlier based on information collected by the radiologists' group for quality assurance purposes.' For the year 1991/92, it was possible to use the radiologists' data to supplement the data from standard returns on referrals, biopsies, and cancers. However, the radiologists' data are available only on a regional basis, and not subdivided by age, so that analyses by region for 1991/92 will be based on the amended figures, while those subdivided by programme or age group will be based on the standard returns. The discrepancy is greatest for the cancer detection rate, where standard returns may underestimate the corrected figures by approximately 8%.
For 1992/93 it was possible to make any necessary amendments from the radiologists' figures to the individual standard returns.
Comparisons of referral rates and cancer detection rates for programmes using single or two view mammography have been made from the combined data for all centres using either protocol.
For calculations of numbers of screening programmes meeting specific targets, only those programmes reporting more than 1000 women screened in any year have been included in the figures for that year.
Results
Overall, 4 061 402 women were invited for screening during the three year period, and 2865474 accepted, an acceptance rate of 70·6%. This rate has not altered substantially during the three years.
In 1992/3, 1 612460 women were invited for screening, indicating that coverage of the 4·5 million women in the eligible population for three yearly invitations is achievable. Table 1 gives the results of the prevalent screen for the three years, and for the total three year period, for women aged 50 + years.
The referral rate for assessment has fallen consistently from 6·9% in 1990/91 to 5·9% in 1992/93; the rate for the three year period is 6·4%. The biopsy rate was similar in 1990/91 and 91/92, but fell slightly in 1992/3, giving an overall rate of 0·9%. The total cancer detection rate increased between 1990/91 and 1991/92, 12474  528  4·2%  53  0·4%  43  3·4  0·6  1·2  1991/92  70615  2112  3·1%  334  0·5%  242  3·4  0·6  0·7  1992/93  205512  6159  3·0%  963  0·5%  813  4·0  0·7  0·9  Total  228601  8799  3·0%  1350  0·5%  1098  3·8 0·6 0·8 For programmes with less than 10% of cancers recorded as unknown size, the detection rate of cancers~10 mm was 1·4 per 1000.
For the three year period, the positive predictive value of referral for assessment was 9·3%. This increased from 8·1 % in 1990/91 to 9·9% in 1992/93. The positive predictive value of a biopsy increased from 62% in 1990/1 to 69% in 1991/92 and 70% in 1992/93. Table 2 shows the results of the prevalent screen by five year age groups for 1992/93. More women are screened in the 50-54 age group than any other. The referral rate decreases with increasing age, while both the biopsy and cancer detection rates increase with age, the latter more markedly. As discussed above, data on size of cancers were not available for individual age groups. Table 3 gives the results of the first routine rescreen for women aged 50 +. In 1990/91, few programmes had moved into the incident screening round, and the figures for this year are based on only seven programmes. By 1992/ 93, 56 programmes were carrying out incident round screening, and over 200 000 women were rescreened. For the three year period the referral rate for assessment from incident screens was 3'0%, the biopsy rate 0'5%, and the total cancer detection rate 3·8 per 1000. From the more restricted data, including 263 893 women screened, the detection rate of in situ cancers was 0·6 per 1000, giving an estimated detection rate of invasive cancers of 3·2 per 1000. The detection rate of invasive cancers~10 mm diameter was 0·8 per 1000, but again 7% of cancers had no size recorded. Very few cancers of >50 mm were recorded, but there may be a tendency for size to be unrecorded for the larger cancers. Forty two screening programmes reported using exclusively single view mammography in the prevalent screening round, while 34 used exclusively two view. Table 4 summarises the prevalent round results for these programmes. The referral rate is higher for single view mammography, and the overall difference of 6'6 v 5·6 is highly significant (P« 0·00 1). The cancer detection rate is higher for two view mammography and the overall difference of 6·2 v 5·6 per 1000 is also significant (P«O·OOl). There is also a small difference in the observed detection rates of small invasive cancers (P<0·05). Table 5 shows the numbers of screening programmes meeting specific targets in the prevalent screening round. Some of the targets set by the NHSBSP have changed during the period under consideration; those included here are the most recent ones, set in 1993. 8 The principal changes have been a reduction in the target for the prevalent round referral rate from 10% to 7% and a change in the malignant to benign ratio target from at least 1:3 to 1:1. The percentage of programmes meeting the current target referral rate of less than or equal to 7% increased from 56% in 1990/91 to 74% in 1992/93, and the percentage with a benign biopsy rate of 5 per 1000 or less has increased from 74% to 90%. The percentage of programmes meeting the cancer detection target rate rose from 69% in 1990/ 91 to 73% in 1991/92, but then fell to 66% in 1992/93. The final row of this table gives the percentage of programmes meeting each target 1-3 show the distribution of rates of individual programmes for the prevalent round referral, biopsy, and invasive cancer detection rates over the three year period. While the referral rates appear to be approximately normally distributed, both the biopsy and cancer detection rates are positively skewed. Figure 4 plots the referral rate for individual programmes against the invasive cancer detection rate, with a small non-significant correlation between the two (r=O'l1, P>0'05), while fig 5 shows the greater correlation between biopsy and invasive cancer detection rates (r= 0'50, P<O·OOI). Both these correlations are slightly higher if in situ cancers are included (r =0'15 and r=0·61 respectively).
Discussion
Despite some initial problems, the system for collecting data from screening programmes is providing valuable information on interim outcome measures. New returns, to be produced for the first time in 1995, will provide more detailed information on the use of FNA cytology, and on the acceptance of screening by women who are being reinvited. Changes to the FHSA software should also enable production of good information on population coverage and rescreening intervals.
The results presented here show that the overall acceptance ofscreening is running close to the anticipated 70%. The rate of referral for assessment at prevalent screens is below 7%, and the biopsy rate is considerably lower than anticipated, partly due to the increase in the use of fine needle aspiration cytology as an assessment procedure in recent years.
The slight fall in the prevalent round cancer detection rate in 1992/93 can be explained by the fact that, as programmes complete their first round of screening, the majority of prevalent screens will be in women aged 50-52 years who have just become eligible for screening. As shown above, the cancer detection rate is lower at younger ages, but the referral rate is higher, and these differences will need to be considered in the future when setting targets for prevalent screens.
The detection rate of small invasive cancers needs to be monitored closely as the programme progresses. It is likely that poor reporting of tumour size is a factor in the apparently low rates observed so far, and this underlines the need for accurate and complete data entry. This problem also hampers the monitoring of advanced cancers in later screening rounds. For some returns it may be possible to reallocate the unknown cases on a proportional basis; this question will be studied in detail in a further paper.
The results in units using exclusively single or two view mammography at prevalent screens support the use of two views, with a lower referral rate and higher cancer detection rate. A similar difference has been demonstrated by when the data for two or three years (as available) is combined. Table 6 shows the percentage ofprogrammes meeting the targets for screening in the incident round. By 1992/93, all programmes were meeting every target except those for the cancer This was achieved with an acceptance rate of 89% at the first screen, 5 an-average screening interval of 24-33 months, and a breast cancer detection rate of 5·0 per 1000, at first screen. By contrast, the United Kingdom trial of early detection (TEDBC) of breast cancer found a 20% reduction in breast cancer mortality over 10 years in women aged 45-64 years offered two yearly mammographic screening, with yearly physical examination." In this study the acceptance at first screen was 66%, with a cancer detection rate at first screen of 5·2 per 1000. However, it can be misleading to compare the mortality reductions reported in screening trials with the 25% "Health of the Nation" target, since the former are based on cumulative mortality over a number of years in women free ofbreast cancer at the start ofscreening, whereas the latter is a reduction in the annual rate in the general population. In the TEDBC there was an average 30% reduction in years 6-10 after the start of the trial, which would translate to a reduction of24% in the general population if20% of breast cancer deaths were due to cases diagnosed before the start of screening. In many screening trials a reduction in breast cancer mortality was preceded by a fall in the rate of advanced disease. Unfortunately in the United Kingdom as a whole, data on tumour size or stage are not complete enough, either historically or at present, to enable any analysis of such trials to be carried out.
The collection in future of more accurate data on size of cancers and on the rates of interval cancers will give a better indication of whether the programme as a whole will meet the target mortality reduction. the UKCCCR trial of one view versus two view mammography," and on the basis of this the Department of Health now recommends that all women be screened by two views at their first appointment. The apparent lack of a corresponding difference in the rate of detection of small invasive cancers may be due to the problems with reporting discussed above.
Those programmes with a higher referral rate are likely to achieve a slightly higher cancer detection rate; this is in contrast to the lack of correlation between rates observed at a regional level. 6 However, based on the observations here, an increase in the referral rate from 5% to 10% would only lead to a corresponding increase in the prevalent round invasive cancer detection rate from 4·5 per 1000 to 4'8 per 1000, and it is possible that both referral rates and cancer detection rates are reflecting the underlying incidence rate of breast cancer, in which case an alteration in the former would not necessarily affect the latter. The observed association between biopsy and cancer detection rates would be expected on the basis of the high malignant to benign ratio.
The Swedish Two Counties study showed a 30% reduction in breast cancer deaths after an average eight years follow up in the population aged 40-74 years offered screening; in the age groups 50-59 and 60-69 years at entry the reduction was 40% and 35% respectively.'? Biopsy rate ('Yo) Figure 5 Biopsy rate versus invasive cancer detection rate (prevalent round, women aged 50+).
